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Abstract
Pain control is an important ethical issue to be considered and con-
stitutes the basis of treatment in premature and term newborns. The 
inadequacy of pain control in these infants in neonatal intensive care 
units leads to neurodevelopmental and behavioral problems in the 
long term. For this reason, it is extremely important to raise aware-
ness of the presence of pain in newborn infants, to reduce invasive 
procedures applied to infants as much as possible, and to minimize 
pain with non-pharmacologic or pharmacologic treatments when it 
is inevitable.
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Öz
Ağrı kontrolü prematüre ve zamanında doğan yenidoğan bebeklerde 
dikkat edilmesi gereken önemli bir etik sorundur ve tedavinin temelini 
teşkil eder. Yenidoğan yoğun bakım birimlerinde izlenen bu bebekler-
de ağrı kontrolünde yetersizlik, bebeklerde ileri dönem nörogelişimsel 
ve davranış ile ilgili sorunlara yol açmaktadır. Bu nedenle yenidoğan 
bebeklerde ağrının varlığı ile ilgili farkındalığı arttırmak, bebeklere uy-
gulanan invaziv girişimleri mümkün olduğunca azaltmak, ağrının ka-
çınılmaz olduğu durumlarda ise bunu farmakolojik olmayan yollardan 
ya da farmakolojik tedavi ile en aza indirmek son derece önemlidir.
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Introduction 
In recent years, the survival rate of newborns followed 
up in neonatal intensive care units (NICUs), especially 
in 24-32–week-old babies, is increasing compared with 
the past. These babies are exposed to recurrent painful 
interventions in the NICU, during a period in which the 
brain develops rapidly and stress perception systems are 
organized. Excessive neuronal activity due to pain in the 
postnatal period causes somatosensory and functional 
changes in pain perception procedure in the long term. 
Therefore, inadequate pain control leads to neurodevel-
opmental and behavioral problems in infants.
One of the most important goals is to prevent recent and 
advanced morbidity during the follow-up of newborn ba-
bies in the NICU and the role of pain control should not 
be forgotten during this phase.
Definition and physiology of pain
The sensation of pain in newborn babies begins from the 
intrauterine period (1). Communication between the cor-
tex and the thalamus begins after the prenatal 20th week (2). 
From birth, peripheral sensitivity to mechanical, thermal, 
and chemical stimuli or nociceptor’s response to primary 
hyperalgia develop and pain signals reach the somatosen-
sory cortex. Babies give physiologic, behavioral, and hor-
monal responses to pain (3). Therefore, with the knowledge 
of the damage and stress caused by pain, it is both a med-
ical and ethical responsibility to develop appropriate pain 
control strategies, especially in premature infants (4).
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Painful interventions to which newborns are exposed 
Some of the painful interventions that newborn babies 
face during intensive care and outpatient follow-up are 
heel stick, venous and arterial vascular interventions, per-
cutaneous central venous catheter insertion, intramuscu-
lar and subcutaneous injections, nasogastric catheter in-
sertion, postural drainage, circumcision, urinary catheter 
insertion, tracheal intubation, endotracheal aspiration, 
lumbar puncture (LP), chest tube insertion and with-
drawal, dressing change, examination for retinopathy of 
prematurity (ROP), and laser therapy.
Heel stick in term and premature infants is more 
painful than venous interventions performed by an ex-
perienced nurse. Endotracheal aspiration, in which con-
siderable pain is felt, should not be performed unless 
absolutely necessary (5). It is also important to control 
pain when pulling a chest tube, which is a very painful 
procedure (6).
There is no precise definition of chronic pain for the new-
born. In newborns, the term long-term or persistent pain 
may be used. Necrotizing enterocolitis (NEC), meningi-
tis, bone fracture, osteomyelitis, septic arthritis, tissue is-
chemia and necrosis, nerve lesion, and skin damage are 
the leading causes of long-lasting pain in newborn in-
fants. This type of pain causes neurologic problems in the 
newborn, similar to acute pain. It is also critical to control 
postsurgical pain (7).
Evaluation of pain response in newborns
The main purpose of evaluating the pain response is to 
determine the cause of the painful condition, the level of 
pain, and the need for intervention against it. In this way, 
it is aimed to avoid inadequate or unnecessary treatment. 
The American Academy of Pediatrics and the Canadian 
Pediatric Association newborn pain control programs rec-
ommend both routine pain control and evaluation before 
and after painful interventions (7).
For all doctors and nurses involved in neonatal care, 
awareness of the presence of pain and treatment needs is 
the first step in effective pain control.
Objective evaluation of pain in newborns can be 
achieved by using structured methods. These structured 
methods should be preferred to include a number of 
physiologic, behavioral or other variables. The method 
to evaluate pain response should be appropriate for ges-
tational age.
Physiologic variables
Physiologic changes observed during painful interven-
tions due to activation of the sympathetic nervous system 
include increased heart rate, increased blood pressure, 
decreased oxygen saturation, increased respiratory rate 
and intracranial pressure, and sweating on the palms. Ad-
ditional known effects are changes in respiratory pattern, 
skin color, and pupil size following painful stimuli (8). 
In some studies, electroencephalography (EEG) or elec-
tromyography (EMG) patterns have also been used to as-
sess pain, but these methods are not yet fully considered 
to guide clinical practice (9).
Behavioral variables
Behavioral variables are considered important indicators 
of pain in newborn infants. Crying (crying forms, dura-
tion, acoustic patterns), facial expressions (scowl, blinking, 
nasolabial wrinkle and opening of the mouth), hand and 
body movements, muscle tone, behavioral status changes, 
ability to disconsolate are counted as the behavioral re-
sponses of newborn babies to pain (8).
Structured methods used in the assessment of pain 
response
There are over 40 methods in the assessment of pain re-
sponse in newborns. The most commonly used methods 
are ”Premature Infant Pain Profile“ (PIPP), ”Crying, Re-
quires Oxygen Saturation, Increased Vital Signs, Expres-
sion, Sleeplessness (CRIES), Neonatal Infant Pain Scale 
(NIPS), Neonatal Pain Agitation and Sedation Scale“ (N-
PASS), “Neonatal Facing Coding System” (NFCS), “Pain 
Assessment Tool” (PAT), “Scale for Use in Newborns” 
(SUN), “Echelle de la Douleur Inconfort Nouveau-Ne” 
(Neonatal Pain and Discomfort Scale, EDIN) and “Ber-
nese Pain Scale for Neonates” (BPSN) (7, 8). Some meth-
ods assess both sedation and pain response at the same 
time (N-PASS and COMFORT).
Choosing the method for pain assessment
The method chosen to assess the pain response in new-
borns should be suitable for the type of pain to be evaluated.
Acute pain: Refers to painful experiences that occur im-
mediately after interventions that cause disruption of 
skin integrity or tissue damage for diagnostic or thera-
peutic purposes. It is the most common type of pain in 
the NICU.
Postoperative pain: This is the type of pain observed in the 
first 24-48 hours in newborn infants after surgery. N-PASS 
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and COMFORT are recently developed scoring systems 
that have been used for evaluating postoperative pain re-
sponse by providing the possibility of evaluating sedation 
with pain (10, 11).
Prolonged / persistent / chronic pain: the term of “chronic 
pain” is not suitable for the neonatal period because the 
concept of chronic pain in children and adults covers a 
period of three months. For this reason, it may be prefer-
able to use the terms ‘prolonged’ or ‘persistent’ pain in 
newborn infants. ‘Prolonged’ or ‘stubborn’ pain in new-
born infants may be due to necrotizing enterocolitis, peri-
tonitis, bone fractures, meningitis, as well as procedures 
such as mechanical ventilation and chest tube insertion. 
N-PASS, COMFORT neo and EDIN scores are available 
for pain assessment in these cases (8).
Among the pain scoring systems that can be used in the 
NICU, one or two methods should be selected accord-
ing to the patient profile, then the doctor, and especially 
the nurses who will score on these methods, should be 
trained.
Pain management in the newborn
Pain management in the neonatal period is very impor-
tant because its permanent effects have been shown. 
There are two management modalities, pharmacologic 
and non-pharmacologic. What is important, however, is 
to reduce and eliminate painful stimuli as much as possi-
ble, rather than to treat them.
Reduction of painful interventions
The first way to reduce the painful event is to reduce in-
terventions in the newborn. What can be done in this 
regard are blood sampling from catheters, planning of 
all samples to be taken at one time in non-catheterized 
patients, and transcutaneous monitoring of blood gases, 
if possible. In particular, the placement of percutaneous 
central catheters may prevent patients from undergoing 
frequent insertions of peripheral catheters. Tracheal as-
piration, which is a very painful procedure in premature 
infants followed in a mechanical ventilator, should not be 
made unnecessarily.
Environmental and behavioral precautions
The non-painful care, treatment and examination proce-
dures should be grouped as much as possible (7). Inter-
vals in which babies can sleep comfortably without being 
touched should be created in their routine procedure. 
Therefore, it is recommended that there should be an in-
terval of at least 2 hours between invasive procedures (12).
The behavioral status of newborn babies is also important 
in the perception of pain. For non-urgent interventions, a 
baby should not be awakened from sleep; calm vigilance 
should be preferred (12). Although no studies have inves-
tigated the effects of sound and light levels on pain re-
sponses in preterm infants, clinical experience shows that 
light and sound levels are kept as low as possible during 
painful interventions.
Using a mechanical lancet during heel stick reduces pain. 
According to the amount of blood to be taken, less painful 
venous blood sampling can be preferred in term infants. 
To reduce the pain observed during the removal of plas-
ters, it is recommended to avoid large plaster surfaces as 
much as possible, and use either mineral oils or silicone-
based special adhesive removers for their removal (13).
Non-pharmacologic methods
Breastfeeding and breast milk, pacifier, skin-to-skin con-
tact, positioning the baby, touching, performing mas-
sage, providing painless sensory stimuli such as sound 
and smell can effectively reduce discomfort and pain in 
preterm and term babies (14).
Breastfeeding or expressed breast milk 
Breast milk is preferred because it is physiologic and has 
no potential adverse effects when compared with other 
options recommended in the treatment of pain in the 
newborn. It has been emphasized that the pain relief ef-
fect of milk can be caused by fat and protein components 
as well as taste. Breastfeeding has similar efficacy to sug-
ary solutions (15). However, it is not possible to apply to 
premature infants who are intubated and not yet able to 
feed orally.
When the effects of breastfeeding – except for contact fac-
tors – were investigated, 2 mL of breast milk given 2 min-
utes before receiving venous blood sample in term babies 
caused a significant decrease in pain responses, but less 
than with a 25% glucose solution (16). In a study conducted 
in preterm infants, 5 mL of expressed breast milk resulted 
in a significant decrease in pain scores (17). Finally, the 
analgesic efficacy of giving expressed breast milk during 
ROP examinations has been demonstrated (18).
In light of the studies conducted, 2-5 mL of breast milk 
– preferably final milk – might be given prior to interven-
tions leading to mild-to-moderate pain.
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Non-nutritive sucking
Non-nutritive sucking (pacifier use) is the most widely 
studied non-pharmacologic method in the treatment 
of neonatal pain. It is effective in reducing pain-related 
stress in both preterm and term babies (14). Pain control 
in infants can be improved by giving pacifiers soaked in 
sugary solutions.
Positioning
During painful interventions, holding babies in the mid-
line flexion posture can ease their calmness. Loosely swad-
dling the baby during interventions was found to be effec-
tive on physiologic and behavioral pain responses (19).
Other non-pharmacologic methods
There are studies showing that touching, performing 
massage, speaking, playing music and in-utero sounds, 
visual stimulation by moving toys has an effect on re-
ducing pain (13). There are some other effective meth-
ods such as giving individualized developmental care, 
smelling vanilla, and hand swaddling by parents prior to 
interventions.
Pharmacologic treatment
Sugary solutions
The oral administration of sugary solutions such as su-
crose, glucose, saccharin, and fructose has analgesic ef-
ficacy in newborns (20). Giving the sugary solutions to-
gether with the pacifier increases their effectiveness.
Sugary solutions may be used prior to minor painful 
procedures (such as heel stick, venous blood sampling, 
venous catheterization, arterial blood sampling, urinary 
catheter insertion, intramuscular or subcutaneous injec-
tion, nasogastric tube insertion, dressing change, removal 
of adhesive tapes). Application of sucrose with topical 
anesthetics was found to be effective in the treatment of 
pain during ROP examinations (21).
In order to observe the effects of sugary solutions, it should 
be given 2 minutes before the intervention onto the an-
terior part of the tongue where the majority of the taste 
buds are located. It is thought that the sucrose with a sug-
ary taste causes endogenous opioid release within the 2 
min interval before the painful intervention is performed.
Sucrose solutions
The most widely used and investigated sugary solutions 
worldwide are sucrose solutions, which are known to 
be effective in newborns with gestational ages of 25-42 
weeks (22). The amount of sucrose shown to be effective 
in the treatment of neonatal pain is between 0.012 and 
0.12 g (0.05 - 0.5 mL 24% sucrose solution) (22). In preterm 
infants 0.2-0.3 mL, in term infants, 1-2 mL of a 12-24% 
concentration sucrose solution can be given. Accessibility 
is low in our country. Dose adjustment is recommended 
with consideration to the postconceptional age (22).
Glucose solutions
Glucose solutions, which can be reached more easily in 
our country, can be considered as an alternative to su-
crose among sugary solutions. The clinically analgesic 
efficacy of 2 mL of 30% glucose given before the venous 
blood collection in term babies has been demonstrated. 
However, the efficacy of 30% glucose is lower than the 
sucrose solution at the same concentration. The adminis-
tration of 2 mL of 20% glucose solution prior to heel stick 
effectively suppresses increased heart rate and behavioral 
pain responses in preterm infants. In patients with heel 
stick or venous blood sampling, analgesic efficacy can be 
observed at concentrations of more than 20% (23).
It was thought that 20-30% glucose might be an alterna-
tive to sucrose for minor painful interventions (24).
Glucose solutions may be given as 1-2 mL at 20-30% con-
centrations in babies with lower gestational age (12).
Adverse effects of sugary solutions
Careful monitoring of vital signs, coughing, and gag re-
flex is required when delivering sugary solutions. Admin-
istration of very frequent and high doses have potential 
adverse effects such as hyperglycemia, fluid overload, and 
necrotizing enterocolitis. Concern for neurologic limita-
tion in infants with low gestational ages continues. When 
the neuromotor development of infants younger than 31 
gestational weeks given either sucrose or water prior to 
each painful interventions within the first seven days of 
life were compared, motor development scores in babies 
receiving sucrose (>10 times per day) were lower at 36-40 
postconceptional age, which was correlated with sucrose 
dose (25). In another study that evaluated the efficacy 
and safety of administering sucrose and pacifier for pain 
control in the first 28 days of life in babies older than 26 
weeks gestational age, no adverse effects or neurologic 
risks were observed (26). Although Holsti et al. reported 
no serious adverse effects in the short term (27), they 
highlighted the negative effects on attention and motor 
development that were found in the only study evaluating 
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neurodevelopmental effects. The suggested mechanisms 
that may lie beneath these possible adverse effects are 
that chronic exposure to sugar can lead to the develop-
ment of alternative pathways associated with attention 
and motor development in the brain.
Topical anesthetics 
Topical anesthetics can be used prior to venous interven-
tions, lumbar puncture, and intravenous catheter inser-
tion. It should be applied half an hour before the proce-
dure in the newborn. It is not appropriate to use topical 
medication during heel stick because pain is more likely to 
be caused by squeezing. It is known that topical lidocaine 
and prilocain preparations causes methemoglobinemia 
in some cases. EMLA cream has been shown to be effec-
tive (28). EMLA cream is recommended to be used care-
fully in preterm infants. Among other topical analgesics, 
tetracaine could be used (29). The complications of topical 
creams might be methemoglobinemia and skin rash (30).
Lidocaine
Lidocaine inhibits axonal conduction by blocking sodium 
ion channels and is used for circumcision procedures.
Opiates (morphine, fentanyl, remifentanil, alfentanil, 
sufentanil)
In the treatment of moderate pain, opiates provide very 
effective treatment. Morphine and fentanyl are the most 
commonly used agents for analgesia and sedation. In 
some NICUs, the more potent sufentanil or the shorter 
duration alfentanil, remifentanil or mixed opiates (tra-
madol) are also recommended for use (31-34). Morphine 
is the most commonly used agent in newborn anesthesia, 
but routine use in ventilated infants is not recommended 
due to the occurrence of hypotension, prolongation of 
mechanical ventilation, and delay of enteral feeding (35).
Fentanyl has less hemodynamic effects and provides 
faster analgesia. Fentanyl can be used when a fast opi-
ate effect is needed and in postoperative pain. Its sig-
nificant adverse effects are bradycardia, hypotension, 
laryngospasm, and chest rigidity (36). In newborns with 
hypotension and in premature babies of 21-26 weeks of 
gestational age, hypotension, bradycardia, intraventric-
ular hemorrhage, impaired intestinal motility, and neu-
rodevelopmental disorders should be considered when 
fentanyl is being used.
The chemical structure of remifentanil is similar to fen-
tanyl but its analgesic effect is three times higher and 
reaches the highest effect in 3-15 minutes. It can be used 
for intubation or short-term procedures such as central 
catheter insertion. Alfentanil’s duration of effect is 20-30 
min. In patients with opioid-induced chest wall rigidity, 
opioid antagonist naloxone is used. If there is no nalox-
one, muscle rigidity can be solved by applying muscle 
paralysis.
When the opiates are used for a long time, instead of 
stopping suddenly, they should be tapered off in order 
to prevent the occurrence of withdrawal symptoms. 
Although there are different approaches in various clin-
ics, an example of a morphine reduction protocol con-
sidering duration of morphine use and Finnegan score is 
given in Figure 1 (37).
Non-opioid pain treatments
Dexmedetomidine
Dexmedetomidine is a selective alpha 2 adrenergic receptor 
agonist. It has a strong sedative and analgesic effect, with 
weak respiratory depression. There are studies reporting 
that it may cause bradycardia and hypothermia in neonates 
(38). In a pharmacokinetic study performed in newborns 
whose gestational age ranged from 28 to 40 weeks, it was 
reported that analgesia and sedation were provided with 
the maintenance dose given at 0.05-0.2 mcg/kg/st dose fol-
lowing a loading dose of 0.05-0.2 mcg/kg (39).
Acetaminophen (Paracetamol)
Acetaminophen inhibits cyclooxygenase (COX)-2 and re-
duces postsurgical opiate use. The most important toxic-
ity is on the liver. However, it is safe and effective at the 
appropriate doses. Dosages according to gestational age 
are as follows:
20-30 mg/kg/day between 24-30 gestational weeks
35-50 mg/kg/day between 31-36 gestational weeks 
50-60 mg/kg/day between 37 and 42 gestational weeks
60-75 mg/kg/day in postnatal 1-3 months (40).
In the recently published Cochrane analysis, it was reported 
that paracetamol does not reduce acute pain, should not 
be used during painful procedures, and the effect of reduc-
ing morphine dose should be investigated (41).
Non-steroidal anti-inflammatory drugs (NSAID)
NSAIDs are mostly used for ductus closure in newborns. 
They have an analgesic, antipyretic, and antiinflamma-
tory effect by inhibiting the effect of COX-1 and COX-2. 
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There is not enough information about the analgesic ef-
fects in neonates. The adverse effects are renal dysfunc-
tion, platelet dysfunction, and pulmonary hypertension 
(42). It has been shown to have positive effects on human 
cerebral circulation.
Ketamine
Ketamine provides analgesia, amnesia, and sedation. 
Studies on the newborn are limited. Ketamine increases 
blood pressure, heart rate, and respiratory rate, and causes 
bronchodilation. It is a good option for intubation or ex-
tracorporeal membrane oxygenation cannulation in the 
hypotensive neonate because it does not affect cerebral 
blood flow (43). In one study, 2 mg/kg was used during en-
dotracheal aspiration (44). It may have neurotoxic effects 
on the developing brain (45).
Other sedatives 
Phenobarbital
This can be used for sedation together with opiates. It has 
no analgesic effect.
Morphine tapering guidelines in the NICU
University of Iowa Children’s Hospital
Figure 1. Morphine tapering guideline
 Written: 06/15/09 Sarah Tierney Pharm D, Julie Lindower MD, MPH &Stephanie Stewart RN, MSN; Updated: 11/17/09, 3/12/2012 
Jonathan Klein, MD and Sarah Tierney, Pharm D, University of Iowa Children’s Hospital, NeonatologyTextbook
Morphine use
Morphine use <3 days
No taper necessary
No withdrawal expected
Morphine use 4-7 days
Finnegan scoring q4 hrs.
Taper morphine drip by 
5 mcg/kg/hr q24 hrs 
to off  as tolerated
Decrease dose every day 
by ~10-30% as tolerated
Score ≥8 or signs and 
symptoms of opioid 
withdrawal
• Treat acute symptoms of withdrawal with 
morphine 0.05-0.1 mg/kg IV or 0.15-0.3 mg/kg 
PO q2 hours PRN
• Do not taper for 24-48 hrs
• Remain at same dose or increase to previous 
dose until signs/ symptoms are well-controlled 
and Finnegan <8 for 12-24 horus.
Then continue taper
Score ≥8
Decrease dose by ~10% every 
OTHER day as tolerated
Continue taper until complete
Continue Finnegan scoring 
q4 hours until taper has been 
discontinued for 48 hours
Morphine use 8-29 days
Finnegan scoring q4 hrs.
Taper by 5 mcg/kg/hr 
q24 hrs until 
10 mcg/kg/hr as tolerated
Once at ≤10 mcg/kg/hr, if tolerated, convert to enteral dose 0.12 mg/kg/dose PO q4 hrs
(see page 2), otherwise continue IV, and taper as below
Morphine use ≥30 days
Finnegan scoring q4 hrs.
Taper morphine drip by
5 mcg/kg/hr q24 hrs to
20 mcg/kg/hr tham taper 
by 2-3 mcg/kg/hr q24 hrs 
until 10 mcg/kg/hr
as tolerated
Finnegan score
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Propofol
Although it has widespread use in young children, there 
is not enough information about its use in the newborn. 
It is recommended to be used with caution because of its 
potential neurotoxic effects, which are inversely propor-
tional to the postconceptional and neonatal ages. It may 
cause hypotension, and decrease heart rate and oxygen 
saturation (46).
Chloral hydrate
Chloral hydrate can be used mostly for sedation, its anal-
gesic effect is not very strong. In one study, an increased 
incidence of apnea and desaturation in term and preterm 
infants was observed (47). If chloral hydrate is used in out-
patient and inpatient settings, a physician to resuscitate 
and the necessary medical equipment should be present 
nearby. Patients treated with chloral hydrate should be 
supervised until complete alertness is achieved.
Benzodiazepines
Benzodiazepines activate gamma aminobutyric acid 
(GABA) receptors, but do not have an analgesic effect. 
These drugs provide sedation and myorelaxation. Its ad-
verse effects are myoclonic jerks, respiratory depression, 
and hypotension. Midazolam is the most commonly used 
benzodiazepine. It has been reported that doubts about 
the use of midazolam have increased gradually and the 
reliability has decreased in the NICU (48). It may cause 
slowing in bilirubin metabolism, especially in neonatal 
asphyxia and premature infants. Routine use is not rec-
ommended.
Analgesia for mechanical ventilation
Mechanical ventilation is the most common cause of 
chronic pain in the NICU. However, despite investiga-
tion in various studies, the ideal analgesia method could 
not be determined in patients who were mechanically 
ventilated. In one of the studies on the use of contin-
uous analgesics or sedatives in mechanically ventilated 
infants, it was observed that the use of morphine for 
seven days or less had no effect on the neurologic re-
sults of the patients (49). In another study, it was found 
that morphine used up to 14 days prolonged the duration 
of mechanical ventilation (50). Fentanyl treatment has 
also been shown to prolong the duration of mechanical 
ventilation. Remifentanil may be used, especially when 
short-term intubation is required (33). In spite of this, 
the NEOPAIN study showed that neurodevelopment 
at school age was better in patients who received mor-
phine (50).
Recommendations for interventions
Here, control methods for painful interventions that are 
frequently applied to newborn babies are presented ac-
cording to international recommendations (51).
Heel stick: Heating, acetaminophen or local anesthetics 
(EMLA cream) prior to heel stick are ineffective in pain 
control. The use of mechanical lancets is less painful. 
Visual-auditory stimuli that distract the attention of the 
baby before the intervention can be applied by the mother 
or nurse. Skin contact with the mother, sugary solutions 
or expressed breast milk with a pacifier if the mother is 
not present during the intervention and other non-drug 
methods suitable for the baby’s clinical condition can be 
used.
Venous, arterial interventions and peripherally inserted 
central catheterization: Before the intervention, the baby 
should be gently positioned. If possible, thin intravenous 
cannulas (24-G, 26-G) should be preferred. Non-drug 
methods such as sugary solutions suitable for the baby’s 
clinical condition, breast milk and pacifier must be ap-
plied. If there is sufficient time, local anesthetic cream 
may be applied to the place where intervention is per-
formed. Peripheral insertion of the central catheter is 
more painful than ordinary venous access because of 
the need for greater venous cannulas. Systemic opioid 
administration may be considered in mechanically ven-
tilated infants. Ketamine may be considered in selected 
cases. Arterial procedures are more painful than venous 
procedures. Local anesthetic may be applied prior to ar-
terial interventions (arterial blood sampling or peripheral 
arterial line insertion) and percutaneously inserted cen-
tral venous catheters.
Umbilical artery and vein catheterization: There is no neu-
ral network in the umbilical cord. If sutures are used to fix 
the catheters, they should be stitched to the cord tissue 
instead of the skin. Non-pharmacologic methods should 
be applied.
Central catheter insertion: Low-dose opioid or deep anal-
gesia/sedation may be applied in accordance with the pa-
tient’s clinical condition.
Intramuscular or subcutaneous injection: If possible, 
medications should be administered via the intravenous 
route. If there is an obligatory intramuscular or subcuta-
neous administration of medications, extra-fine needles 
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should be used. Non-pharmacologic methods or pre-in-
tervention local anesthetic cream may be used.
Tracheal intubation and extubation: Appropriate pain 
control and sedation during elective tracheal intuba-
tion may facilitate the procedure. Intubation performed 
with less effort in shorter time while reducing physio-
logic fluctuations and pain sensations in the baby. Prior 
to elective tracheal intubation, fentanyl (1-3 mcg/kg) or 
morphine (10-30 mcg/kg) and midazolam (50-100 mcg/
kg) may be administered. In selected cases ketamine 1 
mg/kg might be preferred. Low-dose ketamine (0.5 mg/
kg) or dexmedetomidine (0.5 mcg/kg) administration is 
recommended because the respiratory effort can be sup-
pressed by analgesia and sedation if short-term intuba-
tion is planned (e.g. for the administration of surfactant) 
acetaminophen. Atropine (0.02 mg/kg, a minimum of 
0.1 mg/kg) should be given, especially before ketamine 
and dexmedetomidine. In a recent study comparing the 
combinations of different analgesic and sedative drugs 
used during elective tracheal intubation, only the com-
bination of fentanyl and midazolam was reported to 
improve clinical pain scores. When nasal intubation is 
performed, a low-dose (0.3 mL/kg) 2% lidocaine gel fa-
cilitates the progression of the tube. When extubation is 
performed, non-pharmacologic methods for pain con-
trol should be applied after the adhesive tapes are loos-
ened appropriately.
Tracheal aspiration (endotracheal tube suctioning is pos-
sibly more appropriate daha uygun olabilir): Unless nec-
essary, endotracheal tube suctioning should be avoided 
in infants on mechanical ventilation. Suctioning should 
be performed quickly and the aspiration catheter should 
not exceed the tip of the endotracheal tube. Non-phar-
macologic methods (e.g. giving the baby’s hands and feet 
flexion posture) might be applied. Low-dose (0.3 mcg/kg) 
fentanyl may be given systemically.
Chest tube insertion: In addition to non-pharmacologic 
methods, local anesthetic cream should be applied in 
non-emergency conditions, subcutaneous lidocaine in-
jection should be performed in emergency cases. If the 
patient is already intubated and mechanically ventilated, 
systemic opioids can be given; ketamine may be con-
sidered in unintubated newborns. Systemic analgesia is 
recommended when chest physiotherapy is applied. Pain 
may also occur during chest tube withdrawal, therefore 
non-pharmacologic methods, local anesthetics, and sys-
temic analgesia may be given when necessary.
Gastric tube insertion: Non-pharmacologic methods, local 
anesthetics, and gel application may be considered.
Lumbar puncture: Before the intervention, non-pharma-
cologic pain control methods (such as sugary solutions, 
pacifier, breast milk) should be applied according to the 
patients’ condition. Local anesthetic cream should be 
applied if there is sufficient time. There are also centers 
where subcutaneous lidocaine injection is performed.
Suprapubic bladder aspiration: Non-pharmacologic meth-
ods, local anesthetic creams, and subcutaneous lidocaine 
may be given. Intravenous fentanyl (0.5-1.0 mcg/kg) is 
also one of the options for pain control.
Circumcision: In addition to providing non-pharmaco-
logic methods, local anesthetic creams, lidocaine and 
regional anesthesia, it is recommended to administer 
intravenous or oral acetaminophen before and after the 
procedure.
Wound care and dressing: Non-pharmacologic methods, 
local anesthetic creams according to the surface area 
when required, systemic opioids or deep sedation may be 
considered.
Examination for retinopathy of prematurity: Environmen-
tal and behavioral precautions must be taken. In addition, 
non-nutritive suction, breast milk, and sugary solutions 
could be given. Local anesthesia can be achieved with 
0.4% oxybuprocaine or 1% tetracaine, and intravenous 
opioids or ketamine may be used if required during 
RetCam screening. 
Turkish Neonatal Society Recommendations
1. Pain modulation in premature and term babies can-
not be performed like in older children. Therefore, 
they feel more pain.
2. Newborns with untreated recurrent painful interven-
tions may experience permanent neurologic and be-
havioral problems in the future; pain perceptions and 
neuroendocrine stress responses might be impaired.
3. Pain is a vital sign that should be continuously moni-
tored in the NICU.
4. The main purpose of monitoring the pain response is 
determining the painful condition of the baby, deter-
mining the level of pain, and the need for interven-
tion against it.
5. For pain monitoring a structured and multivariable 
method should be used. N-PASS scale can be used in 
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our country (for N-PASS and other pain scales check 
“Newborn and Pain Management Guideline 2015”).
6. There may be limitations in monitoring pain re-
sponse in newborns with neuromuscular block-
ade, on a mechanical ventilator or with neurologic 
deficits. In these cases, physiologic pain responses 
(sympathetic system stimulation symptoms such 
as heart rate variability, pupil dilatation) should be 
closely monitored.
7. The most effective approach in pain control is to re-
duce painful interventions. Therefore, the following 
approaches are recommended for adoption:
 a. Use of catheters for blood sampling 
 b. Taking a blood sample for all tests at once
 c. Use of non-invasive monitoring parameters
 d. Use of peripherally inserted central catheters 
 e. Avoiding routine endotracheal suctioning in  
    babies on mechanical ventilation 
8. Postoperative pain: this pain is observed in the first 24-
48 hours in newborn infants after surgery. The devel-
opment of postoperative pain is already expected by 
healthcare providers and therefore better monitored. 
N-PASS could be used for monitoring pain and se-
dation in postoperative infants starting from the 23rd 
gestational week till the first 100 days of life.
9. Environmental and behavioral precautions that can be 
used are:
 a. Grouping and performing non-painful interven-
tions at one time
 b. No painful interventions for at least 2 hours after 
a painful procedure
 c. Choosing a calm state of alertness for non-ur-
gent interventions
 d. Ensure that the baby feels safe before starting 
the intervention
 e. Keeping light and sound as low as possible dur-
ing painful interventions
 f. Using mechanical lancets for heel stick 
 g. Choosing venous blood sampling in term babies 
– depending on the amount of blood 
 h. Removal of plasters in such a way that the baby 
does not feel pain (use of silicone adhesive re-
movers or wetting of the plasters before removal)
 i. Performing interventions by an experienced 
health caregiver
10. For mild-to-moderate painful interventions, in accor-
dance with the clinical condition of the baby, primar-
ily non-pharmacologic methods, if necessary, a few of 
pharmacologic agents should be applied together by 
targeting synergistic effects.
 a. The most physiologic method is breastfeeding 
of the infant. If the mother can be close to the baby 
during the intervention, skin contact should be en-
sured even if breastfeeding is not possible.
 b. If breastfeeding of the baby is not possible, 2-5 
mL of expressed breast milk, preferably last milk 
should be given.
 c. The use of pacifiers should be ensured during 
painful interventions in all babies who can suck.
 d. The amount and frequency of administration of 
sugary solutions should not be too high in infants 
with a low gestational week. They can be given to 
the anterior of the tongue with pacifiers, if possi-
ble, 2 minutes before the painful interventions.
 i. Sucrose: 0.2-0.3 mL in preterm infants, 1-2 ml 
in term infants at 12-24% concentrations (glu-
cose may be preferred in our country because 
sucrose is expensive and usually unavailable)
 ii. Glucose: 1-2 mL, 20-30% concentrations
 e. Other methods: Facilitated positioning, touch-
ing, performing massage, speaking, eye contact, 
playing music or in-utero sounds, visual stimula-
tion by moving toys, application of individualized 
developmental care principles.
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